-
Simcere Licenses Fermion’s AI-Enabled Painkiller FZ002-037
•
China-based Simcere Pharmaceutical Group Limited (HKG: 2096) has announced a licensing agreement with compatriot firm Fermion, an artificial intelligence (AI) empowered small-molecule drug developer, relating to an investigational SSTR4-targeted painkiller candidate drug, FZ002-037. This strategic partnership aims to advance the development and commercialization of FZ002-037 in Greater China, including mainland…
-
Fermion Secures Series B Financing to Advance AI-Driven Drug Development
•
Guangzhou-based AI biotech Fermion has raised over RMB100 million ($14.8 million) in a Series B financing round led by iFLYTEK Venture Capital, Zhengxuan Capital, Panda Capital, and Challenjers Venture Capital. The funds will advance its core drug pipelines, including a Phase I clinical study for FZ002, a chronic pain candidate,…
